Novel Precision Gene Therapy for Friedreich’s Ataxia with Dr. Gabriel Brooks Solid Biosciences TRANSCRIPT
Download PDFApr 23, 2026
Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic...
Apr 23, 2026
Dr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic...
Mar 17, 2025
Dr. Shankar Musunuri, Chairman of the Board, CEO, and Co-Founder of Ocugen, is developing gene therapies for rare blindness diseases like retinitis pigmentosa and Stargardt disease, which have significant unmet medical needs. The modifier gene therapy approach aims to reset homeostasis and create a healthy environment...
Mar 17, 2025
Dr. Shankar Musunuri, Chairman of the Board, CEO, and Co-Founder of Ocugen, is developing gene therapies for rare blindness diseases like retinitis pigmentosa and Stargardt disease, which have significant unmet medical needs. The modifier gene therapy approach aims to reset homeostasis and create a healthy environment...
Mar 17, 2025
Dr. Shankar Musunuri, Chairman of the Board, CEO, and Co-Founder of Ocugen, is developing gene therapies for rare blindness diseases like retinitis pigmentosa and Stargardt disease, which have significant unmet medical needs. The modifier gene therapy approach aims to reset homeostasis and create a healthy environment...